Published On: Fri, Apr 17th, 2015

Perrigo Announces Launch of Generic Nasal Spray

Kenalog® Spray annual sales were approximately $16 million according to IMS Health.

Kenalog

Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has received final Federal Drug Administration approval for Triamcinolone Acetonide Topical Aerosol, the generic version of Sun Pharma’s Kenalog® nasal spray. Our first to market shipments to our pharmacy customers have commenced.

Kenalog® Spray (Triamcinolone Acetonide Topical Aerosol, USP) is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Annual sales were approximately $16 million according to IMS Health.

Perrigo’s Chairman, President and CEO Joseph C. Papa stated, “This launch is another example of Perrigo’s investment and commitment to making quality healthcare more affordable for all consumers across the globe.”

Read more about: , , , ,

Wordpress site Developed by Fixing WordPress Problems